Ionis Pharmaceuticals (IONS) said Monday the US Food and Drug Administration has accepted for review a new drug application for donidalorsen for prophylaxis to prevent attacks of hereditary angioedema in adults and patients 12 years of age and older.
The regulator has set an action date of Aug. 21, 2025, under the Prescription Drug User Fee Act, the company said.
Hereditary angioedema is a rare genetic disease that causes recurrent attacks of severe swelling in several parts of the body, Ionis said.
Price: 38.72, Change: -0.04, Percent Change: -0.10
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。